Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 9/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.58 |
| ▸ | CDK2 | P24941 | 8/20 | 0.58 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | BRS3 | P32247 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2920079 | 0.91 | AURKA (0.61) | AURKACCNA2CDK2CCNA1NTRK1 | |
| SCHEMBL2920905 | 0.90 | AURKA (0.56) | AURKACCNA2CDK2CCNA1NTRK1 | |
| SCHEMBL2922384 | 0.90 | AURKA (0.64) | AURKACCNA2CDK2CCNA1NTRK1 | |
| SCHEMBL2923431 | 0.89 | AURKA (0.63) | AURKACCNA2CDK2CCNA1NTRK1 | |
| SCHEMBL2918058 | 0.88 | CCNA2 (0.58) | AURKACCNA2CDK2CCNA1NTRK1 | |
| SCHEMBL2922881 | 0.88 | AURKA (0.56) | AURKACCNA2CDK2CCNA1NTRK1 | |
| SCHEMBL2919842 | 0.88 | AURKA (0.56) | AURKACCNA2CDK2CCNA1NTRK1 | |
| SCHEMBL2917763 | 0.87 | CDK2 (0.62) | AURKACCNA2CDK2CCNA1NTRK1 | |
| SCHEMBL2924398 | 0.86 | AURKA (0.65) | AURKACCNA2CDK2CCNA1NTRK1 | |
| SCHEMBL2919919 | 0.85 | CCNA2 (0.56) | AURKACCNA2CDK2CCNA1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320531-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2010-09-08 | — | — | EP | claimed |
| US-7541354-B2 | Bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | claimed |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2003-09-11 | — | — | US | claimed |
| US-20140378423-A1 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-25 | — | — | US | disclosed |
| US-8859778-B2 | 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-10-14 | — | — | US | disclosed |
| US-20140179647-A1 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-26 | — | — | US | disclosed |
| US-8648204-B2 | 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-02-11 | — | — | US | disclosed |
| US-20130289010-A1 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMA SPA (IT) | 2013-10-31 | — | — | US | disclosed |
| US-20130012487-A1 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-01-10 | — | — | US | disclosed |
| US-8273765-B2 | Bicyclo-pyrazoles and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2012-09-25 | — | — | US | disclosed |
| EP-1320531-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2010-09-08 | — | — | EP | disclosed |
| EP-2216327-A1 | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.p.A. (IT) | 2010-08-11 | — | — | EP | disclosed |
| US-20090221632-A1 | Bicyclo-Pyrazoles and Pharmaceutical Compositions Comprising Them | PFIZER ITALIA S.R.L. (IT) | 2009-09-03 | — | — | US | disclosed |
| US-7541354-B2 | Bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | disclosed |
| US-7531531-B2 | Method of treating diseases associated with altered kinase activity with bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-05-12 | — | — | US | disclosed |
| US-20070191386-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-08-16 | — | — | US | disclosed |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289010-A1 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE3A | AURKA 4100/4885CCNA2 4108/4885CDK2 2394/4885 |
| US-20130012487-A1 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE3A | AURKA 4100/4885CCNA2 4108/4885CDK2 2394/4885 |
| US-20140378423-A1 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE3A | AURKA 4100/4885CCNA2 4108/4885CDK2 2394/4885 |
| US-20070191386-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | AURKA 347/4885CCNA2 848/4885CDK2 43/4885 |
| US-20090221632-A1 | Bicyclo-Pyrazoles and Pharmaceutical Compositions Comprising Them | MAP3K20, PLK2, PRKAA1 | AURKA 600/4885CCNA2 1043/4885CDK2 70/4885 |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | AURKA 347/4885CCNA2 848/4885CDK2 43/4885 |
| US-20140179647-A1 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE3A | AURKA 4100/4885CCNA2 4108/4885CDK2 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.